Column 1 Column 2 Column 3 0 2,036,444 Ordinary Shares -$0.053 per Ordinary Share
735,829 Ordinary Shares -$0.07 per Ordinary Share1 6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)Exercise of Options
Exercising of Options, from the resolution on the 14th of Nov 17.
PS : from....
https://www.********/investing/2018/05/06/3-reasons-regeneron-stock-could-start-climbing-aga.aspx
.."As one of the first new eczema treatments for patients that aren't satisfied with topical steroids, Dupixent sales hit an annualized run rate of $556 million during its third quarter after earning approval in the U.S. That isn't nearly as fast as analysts had been predicted, but it still appears capable of generating more than $4 billion annually at its peak. .."
Nice little earner
Ann: Appendix 3B and Notice Under Section 708A, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $752.8M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 43.5¢ | 41.0¢ | $2.989M | 7.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 408524 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |